New Modalities, New Challenges
As biotherapeutic modalities become more complex, existing drug development platforms are struggling to keep up. While cell-based platforms have excelled in developing IgGs and hormone therapies, they often struggle to produce bispecific and multispecific antibodies (BsAbs and MsAbs), antibody-drug conjugates (ADCs), and other novel modalities, especially within shorter timeframes. These challenges demand new protein production technologies to save valuable time and resources.
Go Cell-Free with ALiCE® for High-Throughput Drug Discovery
ALiCE® is a eukaryotic cell-free protein expression system with a proven track record for producing complex and difficult-to-express protein classes at an unparalleled speed.
Unlike traditional cell-based systems, ALiCE® uses a lysate that contains all the necessary components for protein production, including those required for eukaryotic post-translational modifications (PTMs). This eliminates the need for time-consuming cell culture and enables faster production times and higher yields. ALiCE® is uniquely suited for synthesizing a diverse range of proteins, including antibody variants ranging from nanobodies to full-size antibodies, BsAbs, MsAbs, multi-pass transmembrane proteins such as GPCRs, complex therapeutic enzymes, and antigens for panel screening.
With the ability to support rapid high-throughput screening for target discovery and lead identification, ALiCE® provides the ideal solution for biotherapeutics developers looking to accelerate development pipelines. To learn more about the benefits of cell-free expression for drug discovery, read the white paper below.
A Workflow That Couldn’t Get Any Simpler
It’s as easy as adding DNA encoding your protein-of-interest to the ALiCE® lysate. Start with either linear or plasmid DNA, incubate in the ALiCE® lysate for 24–48 hours, then collect and purify your protein. The entire process is streamlined and highly efficient, making it ideal for both small-scale experiments and high-throughput applications. For larger screening projects, ALiCE® kits can be automated on liquid handling devices, enabling scalability to support your development needs.
ALiCE® Along the Early Drug Discovery Continuum
Target Discovery
Access novel drug targets for your characterization or screening initiatives with ALiCE®. Thanks to the presence of native membrane structures in the cell-free lysate, you can produce and stabilize even challenging, difficult-to-express targets, such as G protein-coupled receptors (GPCRs). In a recent study, we successfully expressed the cannabinoid receptor 2 (CB2)—a complex GPCR—in ALiCE® with yields up to 200 μg/mL. The functional activity of CB2 expressed in ALiCE® showed binding kinetics comparable to CHO-expressed proteins, demonstrating its capability to produce high-quality membrane proteins for drug discovery applications.
Lead Identification
Streamline your lead identification process with ALiCE®. Designed for speed and ease of use, ALiCE® allows you to screen more candidates, faster than traditional transient cell-based expression systems, which typically require 10–15 days for protein expression. In contrast, ALiCE® can deliver comparable yields in just 24–48 hours, thanks to a simple, streamlined workflow. The system is also compatible with automation solutions, such as liquid handling devices, enabling high-throughput lead screening with minimal manual intervention, reduced handling complexity, and consistent results for large-scale projects.
Lead Optimization
Benefit from the rapid design-make-test-analyze (DMTA) cycles and seamless scalability to identify the most promising drug candidates for clinical trials. The simple and scalable workflow of ALiCE® enables seamless transitions from microgram through milligram- and gram-scale protein production to support comprehensive characterization. Unlike transient mammalian expression, which typically takes weeks for just one cycle, ALiCE® can complete multiple iterations of DMTA in the same timeframe. This efficiency allows you to quickly refine and optimize your lead candidates, significantly accelerating the drug development process.
Go Beyond Drug Discovery with ALiCE®
Scalable Production
ALiCE® is capable of producing 2g/L or more* of functional protein in reaction volumes of up to 10 L. This is achieved without compromising on yield or requiring extensive process development and optimization.
*2g/L or more achieved with eYFP control, pre-purification. Yields will vary depending on protein and purification strategy.
GMP Compliance
Our robust manufacturing process puts us firmly on the path to achieving GMP compliance. Begin your discovery journey with us and benefit from scaled manufacturing of clinical trial materials as soon as we attain certification.
Connect to discuss your needs:
Want to Try ALiCE® for Your Next Project?
ALiCE® is available as a protein expression kit in various scales and as a protein service. For high-throughput applications and protein manufacture at scale, please get in touch with us for a custom offer.
ALiCE® for Research
Go to Webshop >
ALiCE® for Scale-Up
Go to Webshop >
ALiCE® as a Service
Request Quote >
Coming Soon: ALiCE® for HTP
Discover our all-in-one high-throughput protein expression solution—seamlessly integrate DNA and expression for rapid, efficient protein production with minimal preparation time.
